(Bloomberg)– Thermo Fisher Scientific Inc.s $17.4 billion acquisition of PPD Inc., a provider of clinical and research services to the pharma and biotech industries, is “all about speed” in getting medications to market.Thats the message from Thermo Fisher Chief Executive Officer Marc Casper in outlining the companys objectives for the offer. The cost represents a premium of about 24% to PPDs closing price Tuesday, before reports of a possible deal.Companies like PPD that offer clinical research study services assist run the essential studies that get experimental drugs to market. PPD likewise offers lab services.What Bloomberg Intelligence says:”PPD is one of the biggest contract research organizations, with scale in scientific, main and preclinical laboratory end-markets.

(Bloomberg)– Thermo Fisher Scientific Inc.s $17.4 billion acquisition of PPD Inc., a service provider of scientific and research services to the pharma and biotech industries, is “all about speed” in getting medicines to market.Thats the message from Thermo Fisher Chief Executive Officer Marc Casper in laying out the companys objectives for the deal. The price represents a premium of about 24% to PPDs closing rate Tuesday, prior to reports of a possible deal.Companies like PPD that provide clinical research study services help run the important studies that get speculative drugs to market.”Story continuesShares of Thermo Fisher got 3.6% to $495.43 at 11:28 a.m. in New York trading, while PPD increased 6.9% to $46.98. PPD also offers lab services.What Bloomberg Intelligence states:”PPD is one of the biggest contract research study companies, with scale in clinical, central and preclinical laboratory end-markets.

By